Latest stories on RCUS
Arcus Biosciences Announces New Employment Inducement Grants
StockTitan50 · neutralgeneral
Arcus Biosciences, Inc. (RCUS) files 8-K
SEC 8-K50 · neutralgeneral
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy - Slideshow
Seeking Alpha58 · neutralproduct/pr
Arcus Biosciences prices 14.29M-share offering at $17.50, with a 30-day option for 2.14M more
October 22, 2026
MarketChameleon26 · bearishgeneral
Arcus Biosciences prices $250M public offering at $17.50 per share
Seeking Alpha22 · bearishgeneral
Why is Arcus Biosciences stock sliding today?
Investing.com Markets38 · neutralgeneral
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
StockTitan22 · bearishgeneral
Arcus Biosciences slides 20% on stock offering, kidney-cancer data
Seeking Alpha22 · bearishgeneral
Arcus Biosciences stock falls on public offering announcement
Investing.com Markets26 · bearishgeneral
Arcus Biosciences $250M Spot Secondary; price range $17.50-$18.50
The Fly26 · bearishgeneral
Arcus Biosciences announces common stock offering, no amount given
The Fly26 · bearishgeneral
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
PR Newswire34 · bearishgeneral
Arcus Biosciences announces public stock offering
Seeking Alpha26 · bearishgeneral
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
StockTitan24 · bearishgeneral
Arcus Biosciences, Inc. (RCUS) files 8-K
SEC 8-K50 · neutralgeneral
Arcus Biosciences falls -8.3%
The Fly34 · bearishgeneral
Truist raises Arcus Biosciences stock price target on drug data
Investing.com Analyst Ratings64 · neutralanalyst
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Seeking Alpha63 · neutralanalyst
Arcus Biosciences price target raised to $41 from $40 at Truist
The Fly63 · neutralanalyst
Arcus Biosciences price target raised to $50 from $45 at Citi
The Fly64 · neutralanalyst
Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript
Seeking Alpha58 · neutralproduct/pr
Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug
Seeking Alpha64 · neutralanalyst
Arcus Biosciences Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
Investors.com74 · bullishproduct/pr
Arcus highlights nearly three-year median overall survival signal for casdatifan in late-line kidney cancer
October 20, 2026
MarketChameleon74 · bullishproduct/pr
Arcus Biosciences unveils promising kidney cancer data
TipRanks64 · neutralproduct/pr